M E Heft Neal1, E Gensterblum-Miller1, A D Bhangale1, A Kulkarni1, J Zhai2, J Smith1, C Brummel1, S K Foltin1, D Thomas3, H Jiang4, J B McHugh3, J C Brenner5. 1. Department of Otolaryngology - Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, MI, United States. 2. Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, United States. 3. Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, United States. 4. Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, United States; Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI, United States. 5. Department of Otolaryngology - Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, MI, United States; Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI, United States; Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, United States. Electronic address: chadbren@umich.edu.
Abstract
OBJECTIVES: Salivary gland tumors are comprised of a diverse group of malignancies with widely varying prognoses. These cancers can be difficult to differentiate, especially in cases with limited potential for immunohistochemistry (IHC)-based characterization. Here, we sought to define the molecular profile of a rare salivary gland cancer called hyalinizing clear cell carcinoma (HCCC), and identify a molecular gene signature capable of distinguishing between HCCC and the histopathologically similar disease, mucoepidermoid carcinoma (MEC). MATERIALS AND METHODS: We performed the first integrated full characterization of five independent HCCC cases. RESULTS: We discovered insulin-like growth factor alterations and aberrant IGF2 and/or IGF1R expression in HCCC tumors, suggesting a potential dependence on this pathway. Further, we identified a 354 gene signature that differentiated HCCC from MEC, and was significantly enriched for genes with an ATF1 binding motif in their promoters, supporting a transcriptional pathogenic mechanism of the characteristic EWSR1-ATF1 fusion found in these tumors. Of the differentially expressed genes, IGF1R, SGK1 and SGK3 were found to be elevated in the HCCCs relative to MECs. Finally, analysis of immune checkpoints and subsequent IHC demonstrated that CXCR4 protein was elevated in several of the HCCC cases. CONCLUSION: Collectively, our data identify an ATF1-motif enriched gene signature that may have clinical utility for molecular differentiation of HCCCs from other salivary gland tumors and discover potential actionable alterations that may benefit the clinical care of recurrent HCCC patients.
OBJECTIVES: Salivary gland tumors are comprised of a diverse group of malignancies with widely varying prognoses. These cancers can be difficult to differentiate, especially in cases with limited potential for immunohistochemistry (IHC)-based characterization. Here, we sought to define the molecular profile of a rare salivary gland cancer called hyalinizing clear cell carcinoma (HCCC), and identify a molecular gene signature capable of distinguishing between HCCC and the histopathologically similar disease, mucoepidermoid carcinoma (MEC). MATERIALS AND METHODS: We performed the first integrated full characterization of five independent HCCC cases. RESULTS: We discovered insulin-like growth factor alterations and aberrant IGF2 and/or IGF1R expression in HCCC tumors, suggesting a potential dependence on this pathway. Further, we identified a 354 gene signature that differentiated HCCC from MEC, and was significantly enriched for genes with an ATF1 binding motif in their promoters, supporting a transcriptional pathogenic mechanism of the characteristic EWSR1-ATF1 fusion found in these tumors. Of the differentially expressed genes, IGF1R, SGK1 and SGK3 were found to be elevated in the HCCCs relative to MECs. Finally, analysis of immune checkpoints and subsequent IHC demonstrated that CXCR4 protein was elevated in several of the HCCC cases. CONCLUSION: Collectively, our data identify an ATF1-motif enriched gene signature that may have clinical utility for molecular differentiation of HCCCs from other salivary gland tumors and discover potential actionable alterations that may benefit the clinical care of recurrent HCCC patients.
Authors: Rebecca Hoesli; Andrew C Birkeland; Andrew J Rosko; Mohamad Issa; Kelsey L Chow; Nicole L Michmerhuizen; Jacqueline E Mann; Steven B Chinn; Andrew G Shuman; Mark E Prince; Gregory T Wolf; Carol R Bradford; Jonathan B McHugh; J Chad Brenner; Matthew E Spector Journal: Oral Oncol Date: 2017-12-23 Impact factor: 5.337
Authors: Brittny N Tillman; Megan Yanik; Andrew C Birkeland; Chia-Jen Liu; Daniel H Hovelson; Andi K Cani; Nallasivam Palanisamy; Shannon Carskadon; Thomas E Carey; Carol R Bradford; Scott A Tomlins; Jonathan B McHugh; Matthew E Spector; J Chad Brenner Journal: Head Neck Date: 2016-02-05 Impact factor: 3.147
Authors: Andrew C Birkeland; Megan Yanik; Brittny N Tillman; Megan V Scott; Susan K Foltin; Jacqueline E Mann; Nicole L Michmerhuizen; Megan L Ludwig; Morgan M Sandelski; Christine M Komarck; Thomas E Carey; Mark E P Prince; Carol R Bradford; Jonathan B McHugh; Matthew E Spector; J Chad Brenner Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-06-01 Impact factor: 6.223
Authors: Paul L Swiecicki; Greg Durm; Emily Bellile; Apurva Bhangale; J Chad Brenner; Francis P Worden Journal: Invest New Drugs Date: 2020-01-24 Impact factor: 3.651
Authors: Maria J Camões; Paula Paulo; Franclim R Ribeiro; João D Barros-Silva; Mafalda Almeida; Vera L Costa; Nuno Cerveira; Rolf I Skotheim; Ragnhild A Lothe; Rui Henrique; Carmen Jerónimo; Manuel R Teixeira Journal: PLoS One Date: 2012-11-19 Impact factor: 3.240
Authors: Josephine K Dermawan; Fabio Vanoli; Laurie Herviou; Yun-Shao Sung; Lei Zhang; Samuel Singer; William D Tap; Ryma Benayed; Tejus A Bale; Jamal K Benhamida; Brendan C Dickson; Cristina R Antonescu Journal: Mod Pathol Date: 2022-03-28 Impact factor: 8.209